6 Top Healthcare Stocks to Buy Now, According to Analysts
Healthcare stocks lagged behind the S&P 500 in 2025, weighed down by policy uncertainty. Yet, the sector often proves to be a resilient defensive play during economic downturns, as consumers rarely cut back on essential prescriptions or postpone critical procedures. This inherent demand, coupled with powerful demographic trends, grants healthcare a unique “economic immunity.”
The backdrop is a massive and growing market. The United States operates the world’s most expensive healthcare system, accounting for nearly half of the estimated $9.8 trillion in global spending. Furthermore, the Centers for Medicare & Medicaid Services (CMS) projects U.S. health expenditures to grow at a 5.8% annual rate through 2033, outpacing both inflation and GDP growth. This growth is propelled by three undeniable forces: 1) irreversible demographics, as aging baby boomers drive demand for chronic disease management and surgeries; 2) an accelerating innovation cycle, from GLP-1 drugs to surgical robots; and 3) the non-discretionary nature of medical consumption.
This recent underperformance, however, may have created an attractive valuation entry point for long-term investors. CFRA analysts have identified six standout stocks based on fundamentals, growth catalysts, and valuation.
1. Eli Lilly (LLY): A Dual Engine in Metabolism & Neuroscience
- Thesis: Positioned at the epicenter of two megatrends. Its GLP-1 drug Zepbound benefits from expanding insurance coverage, while Alzheimer’s drug Kisunla represents a breakthrough in neuroscience.
- Catalyst: A Medicare cap on Zepbound copays at $50/month starting April 2025 should boost adoption. Kisunla’s approval in key markets opens a multi-billion dollar opportunity.
- Risk: High expectations are baked into the valuation; pricing pressure may intensify with competition.
- Price Target: $1,211 (~16% implied upside).
2. AbbVie (ABBV): A Blueprint for Successful Transition
- Thesis: A model for navigating a “patent cliff.” Rapid growth from new immunology drugs Skyrizi and Rinvoq is effectively offsetting the decline of blockbuster Humira.
- Catalyst: Continued penetration of Skyrizi across multiple indications. Strong cash flow supports a robust dividend and strategic M&A.
- Risk: Fierce competition in immunology requires continuous demonstration of product superiority.
- Price Target: $275 (~22% upside).
- Thesis: Combines a monopolistic advantage with market expansion. Its da Vinci surgical system creates high switching costs and a deep clinical data moat.
- Catalyst: Expansion into complex procedures like cardiac and colorectal surgery increases system utilization. A global hospital upgrade cycle, especially in emerging markets, provides tailwinds.
- Risk: Subject to capital expenditure cycles; economic weakness could delay hospital purchasing decisions.
- Price Target: $645 (~30% upside).
4. Boston Scientific (BSX): The Stealth Champion in Cardiovascular Innovation
- Thesis: A pipeline reaching prolific commercialization. It holds several “best-in-class” products in structural heart and electrophysiology.
- Catalyst: The Watchman FLX left atrial appendage occluder is becoming a new standard for stroke prevention. The Farapulse PFA system has potential to disrupt cardiac ablation.
- Risk: Past questions about execution require monitoring of commercial rollout for new products.
- Price Target: $125 (~36% upside).
5. Pfizer (PFE): Remaking Itself for the Post-COVID Era
- Thesis: Aggressive M&A to rebuild its growth profile. The Seagen acquisition vaults it into the top tier of ADC (antibody-drug conjugate) oncology, while the Metsera deal provides an entry into the GLP-1 obesity market.
- Catalyst: Seagen’s ADC platform should create strong synergies with Pfizer’s oncology pipeline. Legacy assets like Eliquis and Prevnar provide stable cash flow.
- Risk: High integration risk; post-acquisition R&D productivity remains to be proven.
- Price Target: $31 (~16% upside).
6. Stryker (SYK): Dual-Driven by Orthopedics & Robotics
- Thesis: Building a robotic moat within traditional orthopedics. Its Mako system for joint replacement holds significant clinical and commercial leadership.
- Catalyst: The shift of procedures to outpatient settings favors its portfolio. Future expansion of Mako into spine and shoulder surgery could double its addressable market.
- Risk: Orthopedic implants face ongoing reimbursement pressure.
- Price Target: $418 (~14% upside).
Investment Strategy & Risks
Investors can tailor exposure based on risk appetite: Aggressive growth seekers may focus on Lilly and Boston Scientific for disruptive tech; those preferring steady value might favor AbbVie and Stryker for cash flow and dividends; while turnaround bets could look to Pfizer for post-merger integration success.
Key risks warrant caution: 1) Policy Risk: U.S. drug pricing and payment reforms could pressure margins; 2) Development Risk: Clinical failures or commercial disappointments can cause sharp volatility; 3) Valuation Risk: Lofty premiums for some leaders may limit near-term upside.
The long-term thesis for healthcare is rooted in the enduring human pursuit of health. While short-term policy clouds may cause volatility, the powerful trifecta of demographics, innovation, and spending growth remains unstoppable. These six companies—whether commanding dominant franchises, demonstrating successful transformation, or building deep competitive moats—offer investors “core holdings” capable of navigating various economic climates. In an era of persistent uncertainty, investing in industries that address fundamental human needs may provide the clearest path forward.
Biotechnology
Contrarian Investing
Medical Device
Pharmaceutical
Robot
